DDInter458 DDInter62
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. Studies establishing the efficacy of Ambrisentan included patients with both idiopathic or heritable pulmonary arterial hypertension and those with pulmonary arterial hypertension associated with connective tissue diseases. Patients studied displayed symptoms and etiologies predominantly of WHO Functional Class II-III. As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A7
CYP3A7 {u} (Gene) is bound by {v} (Compound) Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ambrisentan
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A7
CYP3A7 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ambrisentan
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ambrisentan
Cyclosporine {u} (Compound) downregulates {v} (Gene) MELK
MELK {u} (Gene) is upregulated by {v} (Compound) Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ambrisentan
Cyclosporine {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ambrisentan
Cyclosporine {u} (Compound) downregulates {v} (Gene) MELK
MELK {u} (Gene) is downregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ambrisentan
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Ambrisentan
Cyclosporine {u} (Compound) upregulates {v} (Gene) WFS1
WFS1 {u} (Gene) is downregulated by {v} (Compound) Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ambrisentan
Cyclosporine {u} (Compound) downregulates {v} (Gene) MELK
MELK {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ambrisentan
Cyclosporine {u} (Compound) downregulates {v} (Gene) DNTTIP2
DNTTIP2 {u} (Gene) is downregulated by {v} (Compound) Fluconazole
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ambrisentan
Cyclosporine (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Fluconazole (Compound) and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ambrisentan
Cyclosporine (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Ambrisentan
Cyclosporine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ambrisentan
Cyclosporine (Compound) downregulates MELK (Gene) and MELK (Gene) is upregulated by Fluconazole (Compound) and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ambrisentan
Cyclosporine (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Fluconazole (Compound) and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ambrisentan
Cyclosporine (Compound) downregulates MELK (Gene) and MELK (Gene) is downregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Ambrisentan
Cyclosporine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Ambrisentan
Cyclosporine (Compound) upregulates WFS1 (Gene) and WFS1 (Gene) is downregulated by Fluconazole (Compound) and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ambrisentan
Cyclosporine (Compound) downregulates MELK (Gene) and MELK (Gene) is downregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Ambrisentan
Cyclosporine (Compound) downregulates DNTTIP2 (Gene) and DNTTIP2 (Gene) is downregulated by Fluconazole (Compound) and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ambrisentan